Evidence map›Paper›PMID 41614194›Full record

ArticleJACS Au2026

PSMA-Targeting Chimeras for Cell-Type-Specific Degradation of Surface Immune Checkpoint Protein PD-L1.

Yuqing Luo, Xiaoxiao Gong, Keren Peng, Yanqing Yang, Meng Chen, Yu Guo, Kang Chen, Jinming Gao, Xing Su, Jinxin Che and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuqing LuoInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, Zhejiang 310058, China.
Xiaoxiao GongGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Keren PengGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Yanqing YangZhejiang Key Laboratory of Cell and Molecular Intelligent Design and Development, Institute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.ORCID https://orcid.org/0009-0001-3252-9756
Meng ChenInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, Zhejiang 310058, China.
Yu GuoInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, Zhejiang 310058, China.
Kang ChenInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, Zhejiang 310058, China.
Jinming GaoShaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, 3 Taicheng Road, Yangling, 712100, Shaanxi China.
Xing SuDepartment of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China.
Jinxin CheInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, Zhejiang 310058, China.ORCID https://orcid.org/0000-0001-7202-9214
Xiaowu DongInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, Zhejiang 310058, China.ORCID https://orcid.org/0000-0002-2178-4372
Jiang-Jiang TangShaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, 3 Taicheng Road, Yangling, 712100, Shaanxi China.ORCID https://orcid.org/0000-0003-2598-3456
Xiaolei ZhangGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.ORCID https://orcid.org/0000-0003-2395-2453
Peng TengInstitute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Rd, Hangzhou, Zhejiang 310058, China.ORCID https://orcid.org/0000-0002-7412-9646
Ruhong ZhouZhejiang Key Laboratory of Cell and Molecular Intelligent Design and Development, Institute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.ORCID https://orcid.org/0000-0001-8624-5591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysosome-targeting chimera technology has been utilized to degrade proteins of interest via the endosome-lysosome pathway mediated by endogenous ligands that engage cell-surface transmembrane proteins. Despite their promising potential, current approaches remain limited by the tissue-specific expression of surface receptors required for endocytosis. Prostate-specific membrane antigen (PSMA) is highly and specifically expressed in prostate cancer, driving significant progress in PSMA-targeted therapies, particularly radioligand therapy and antibody-drug conjugates, through PSMA-mediated internalization. Leveraging this phenomenon, we developed PSMA-targeting chimeras (PATACs), a novel and readily accessible class of heterobispecific small molecules designed for membrane protein degradation. PATACs facilitate the cointernalization of a target protein of interest, directing it into the lysosomal degradation pathway. As a proof of concept,

Indexed as

molecular dynamics simulationsPD-L1prostate cancer cell-specificPSMAtargeted protein degradation

Identifiers

PMID41614194
PMCPMC12848674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.